Medical/Pharmaceuticals
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms
The company's PIONEER™, EDEN™, and RAVEN™ platforms mimic the human immune system to simplify the drug development process for a range of diseases LONDON, Oct. 14, 2021 /PRNewswire/ -- Based on its recent analysis of the European AI-enabled drug discovery market,Frost & Sullivan recognizes Evaxio...
2021-10-14 19:30
2370
BioAgilytix Closes Acquisition of Australia-based 360biolabs®
Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 /...
2021-10-14 19:00
2169
21 Swiss Startups to take the Stage at China's Hottest Tech Expos
SHANGHAI, Oct. 14, 2021 /PRNewswire/ -- 21 Swiss startups will be joining the primely-located SwissTech Pavilions at China Hi-Tech Fair fromNovember 17 - 21, 2021 in Shenzhen, and Tech G Shanghai International Consumer Electronics Show fromJanuary 13 - 15, 2022 in Shanghai. The world-class Swiss...
2021-10-14 16:18
1520
A China-developed COVID-19 vaccine is conducting clinical trial in Philippines
CHENGDU, China, Oct. 14, 2021 /PRNewswire/ -- Philippines is currently conducting, along with other countries includingIndonesia, Kenya, and Mexico, a Phase III clinical trial of Recombinant COVID-19 Vaccine (Sf9 cells) produced by WestVac Biopharma Co., LTD and National Key Laboratory of Bioth...
2021-10-14 12:58
2705
Restart-A-Heart Day - Targets Aussie Women
MELBOURNE, Australia, Oct. 14, 2021 /PRNewswire/ -- Recent studies reveal women
are 27% less likely to receive CPR in a public setting compared to men.
2021-10-14 09:15
2920
New Information from NCCN on Most Common Type of Cancer; Diagnosed in Millions Every Year
New NCCN Guidelines for Patients: Basal Cell Skin Cancer empowers patients and caregivers with knowledge about this widespread, preventable, and easily-cured cancer plus the rare subset that requires more aggressive treatment. PLYMOUTH MEETING, Pa., Oct. 13, 2021 /PRNewswire/ -- The National Com...
2021-10-13 22:07
4032
One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows
* The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalizations. * Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decli...
2021-10-13 20:30
5863
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will...
2021-10-13 20:30
4545
Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week inShanghai (IBIWS) running from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote speech at the "2021 Future ...
2021-10-13 20:20
4613
World Thrombosis Day Campaign Unites Thousands of Global Partners to Shine a Spotlight on Blood Clots as an Urgent Health Problem
In its Eighth Year, the Global Campaign Aims to Increase Public Awareness of Blood Clots that Result from Hospitalization and COVID-19 CHAPEL HILL, N.C., Oct. 13, 2021 /PRNewswire/ -- Today, the World Thrombosis Day campaign encourages the public, healthcare professionals and policy makers to ke...
2021-10-13 14:19
2550
Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America
SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced
its partnership with IAS - the International AIDS Society - to expand theMe &
My Healthcare Provider campaign
2021-10-13 13:00
2189
New Dymax MD(R) 1040-M Autoclave Resistant Adhesive for Medical Instruments and Assembly
SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- Dymax Corporation, leading manufacturer of rapid curing materials and equipment, unveils its newest product, 1040-M, as part of its MD® line of adhesives for medical device assembly applications. Designed to be autoclave resistant for more than 100 cycles...
2021-10-13 10:00
2706
SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases
SOPHiA Clinical Exome Solution v3 offers a streamlined end-to-end workflow to facilitate the assessment of challenging Mendelian disorders BOSTON and LAUSANNE, Switzerland, Oct. 13, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing...
2021-10-13 05:16
2910
DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing itsBiomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed ...
2021-10-12 22:52
4048
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
* Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors * Investment serves customers in addressing larger patient populations with new curative treatments * Enables suspension production of viral vectors up to...
2021-10-12 21:00
4489
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...
2021-10-12 20:30
3885
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle ce...
2021-10-12 20:23
3183
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produc...
2021-10-12 10:30
3620
Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Association for the Study of Liver Diseases
HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session...
2021-10-12 08:30
4619
Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline
HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an$70 million Series C financing. The f...
2021-10-12 08:00
4811
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 281 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24713